Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 30;9:20271. doi: 10.1038/s41598-019-56854-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effect of valproic acid (VPA) and hydralazine on mammary tumor burden. (a) Mammary tumor burden, assessed by measuring tumor volume (diameter × width), was significantly higher (p = 0.029) in the offspring of high fat (HF) fed dams (n = 28) during 20 week tumor monitoring period than in control (CON) offspring (n = 30). (b) The difference was lost (p = 0.16) by treatment with VPA/hydralazine (abbreviated as EPI) (n = 18 in CON-EPI and n = 30 in HF-EPI). (c) VPA/hydralazine treatment did not change (p = 0.13) mammary tumor burden in HF offspring. (d) VPA/hydralazine treated CON mice had significantly higher (p = 0.027) mammary tumor burden than non-treated CON mice. Means and SEM of tumor volume at each tumor monitoring week are shown; * indicates statistical significance during weeks when it reached p < 0.05. Differences were analyzed according to 2-way Repeated Measures ANOVA followed by Holm Sidak test.